017180 — Myungmoon Pharm Co Income Statement
0.000.00%
Last trade - 00:00- KR₩53bn
- KR₩152bn
- KR₩195bn
Annual income statement for Myungmoon Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 144,760 | 152,135 | 169,567 | 186,443 | 195,247 |
| Cost of Revenue | |||||
| Gross Profit | 62,338 | 78,101 | 95,354 | 104,965 | 106,918 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 151,089 | 145,705 | 169,340 | 185,369 | 188,412 |
| Operating Profit | -6,330 | 6,430 | 228 | 1,074 | 6,835 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6,598 | 2,652 | -4,782 | -3,744 | 2,648 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6,804 | 7,976 | -4,874 | -3,790 | 1,418 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6,865 | 7,868 | -4,525 | -3,035 | 1,895 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6,865 | 7,868 | -4,525 | -3,035 | 1,895 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -212 | 233 | -121 | -64.1 | 56.3 |
| Dividends per Share |